APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, in the presence of CML, co-injection of an apoA-I:CIGB-258 mixture yielded significantly higher embryo survivability, in a dose-dependent manner, of CIGB-258: 47 ± 3% (p < 0.01), 78 ± 2% (p < 0.001), and 82 ± 2% (p < 0.001) for apoA-I:CIGB-258 molar ratios of 1:0.1, 1:0.5, and 1:1, respectively.